Search Results - "Salyers, A K"

In vitro and in vivo characterization of A‐796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models by Yao, B B, Hsieh, G C, Frost, J M, Fan, Y, Garrison, T R, Daza, A V, Grayson, G K, Zhu, C Z, Pai, M, Chandran, P, Salyers, A K, Wensink, E J, Honore, P, Sullivan, J P, Dart, M J, Meyer, M D

“…Background and purpose: Selective cannabinoid CB2 receptor agonists have demonstrated analgesic activity across multiple preclinical pain models. AM1241 is an…”
Get full text

Characterization of nerve growth factor-induced mechanical and thermal hypersensitivity in rats by Mills, C.D., Nguyen, T., Tanga, F.Y., Zhong, C., Gauvin, D.M., Mikusa, J., Gomez, E.J., Salyers, A.K., Bannon, A.W.

“…Background Injection of nerve growth factor (NGF) produces mechanical and thermal hypersensitivity in rodents and humans. Treatment with sequestering…”
Get full text

In vitro and in vivo characterization of A‐796260: a selective cannabinoid CB 2 receptor agonist exhibiting analgesic activity in rodent pain models by Yao, B B, Hsieh, G C, Frost, J M, Fan, Y, Garrison, T R, Daza, A V, Grayson, G K, Zhu, C Z, Pai, M, Chandran, P, Salyers, A K, Wensink, E J, Honore, P, Sullivan, J P, Dart, M J, Meyer, M D

Get full text

Assessment of platelet function assays by Nicholson, Nancy S., Panzer-Knodle, Susan G., Haas, Neal F., Taite, Beatrice B., Szalony, James A., Page, Jimmy D., Feigen, Larry P., Lansky, David M., Salyers, Anita K.

“…Optical aggregometry, traditionally used to assess platelet function, is highly dependent on sample preparation and technical procedure; as a result, data from…”
Get full text

SC-54684A : an orally active inhibitor of platelet aggregation by NICHOLSON, N. S, PANZER-KNODLE, S. G, ENGLEMAN, V. W, HERIN, M, JACQMIN, P, FEIGEN, L. P, SALYERS, A. K, TAITE, B. B, SZALONY, J. A, HAAS, N. F, KING, L. W, ZABLOCKI, J. A, KELLER, B. T, BROSCHAT, K

“…Intravenous therapy has been shown to be beneficial in the prevention of acute platelet-associated thrombotic events. However, orally active agents would be…”
Get full text

Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A by SZALONY, J. A, HAAS, N. F, SALYERS, A. K, TAITE, B. B, NICHOLSON, N. S, MEHROTRA, D. V, FEIGEN, L. P

“…Platelet aggregation is important in thrombotic events, and platelets play a major role in the etiology of several cardiovascular diseases. Platelet…”
Get full text

The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis by FREDERICK, L. G, SULEYMANOV, O. D, KING, L. W, SALYERS, A. K, NICHOLSON, N. S, FEIGEN, L. P

“…Fibrinogen receptor antagonists block the fibrinogen-platelet interaction at the GPIIb/IIIa receptors and inhibit thrombus formation. SC-54701 is the active…”
Get full text

Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749) by Nicholson, N S, Panzer-Knodle, S G, Salyers, A K, Taite, B B, King, L W, Miyano, M, Gorczynski, R J, Williams, M H, Zupec, M E, Tjoeng, F S

“…Arginine-glycine-aspartic acid (RGD) is the minimal sequence in fibrinogen that leads to recognition and binding to the glycoprotein IIb/IIIa platelet receptor…”
Get more information

Protective effect of oral xemilofiban in arterial thrombosis in dogs: Increased activity in combination with aspirin by FREDERICK, L. G, SULEYMANOV, O. D, SZALONY, J. A, TAITE, B. B, SALYERS, A. K, KING, L. W, FEIGEN, L. P, NICHOLSON, N. S

“…Inhibition of platelet aggregation by preventing the binding of fibrinogen to glycoprotein (GP) IIb/IIIa on activated platelets results in antithrombotic…”
Get full text

A new method for measurement of plasma concentration of orally active glycoprotein IIb/IIIa antagonists by Salyers, A K, Szalony, J A, Taite, B B, Haas, N F, Mehrotra, D V, Feigen, L P, Nicholson, N S

“…A bioassay for determining concentrations of antiplatelet compounds in plasma or aqueous solution has been developed. The method uses an aliquot of plasma from…”
Get more information

In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent by Nicholson, N S, Panzer-Knodle, S G, Salyers, A K, Taite, B B, King, L W, Miyano, M, Gorczynski, R J, Williams, M H, Zupec, M E, Tjoeng, F S

“…Platelet aggregation requires binding of fibrinogen (fgn) to activated platelets and inhibition of this binding blocks platelet aggregation. Synthetic peptides…”
Get more information

Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist by Nicholson, Nancy S., Abood, Norman A., Panzer-Knodle, Susan G., Frederick, Leo G., Page, Jimmy D., Salyers, Anita K., Suleymanov, Osman D., Szalony, James A., Taite, Beatrice B., Anders, Robert J.

“…A key role has been established for platelet activation and thrombus formation in the pathogenesis of acute coronary syndromes, and restenosis after…”
Get full text

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor by Zablocki, Jeffery A, Miyano, Masateru, Garland, Robert B, Pireh, Daisy, Schretzman, Lori, Rao, Shashidhar N, Lindmark, Richard J, Panzer-Knodle, Susan G, Nicholson, Nancy S

“…Peptide mimetics of the RGDF sequence in which Arg-Gly has been replaced with 5-(4-amidinophenyl)pentanoyl mimetic has led to a 1000-fold increase in…”
Get full text

Simultaneous determination of ventricular function and systemic hemodynamics in the conscious rat by Salyers, A K, Rozek, L F, Bittner, S E, Walsh, G M

“…This study describes a method that utilizes a combination of the Millar transducer and Columbus thermistor in the conscious, spontaneously hypertensive rat and…”
Get more information

In vitro and in vivo characterization of A-796260: a selective cannabinoid CB sub(2) receptor agonist exhibiting analgesic activity in rodent pain models by Yao, B B, Hsieh, G C, Frost, J M, Fan, Y, Garrison, T R, Daza, A V, Grayson, G K, Zhu, C Z, Pai, M, Chandran, P, Salyers, A K, Wensink, E J, Honore, P, Sullivan, J P

“…Background and purpose: Selective cannabinoid CB sub(2) receptor agonists have demonstrated analgesic activity across multiple preclinical pain models. AMI 241…”
Get full text

H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats by HSIEH, Gin C, CHANDRAN, Prasant, WETTER, Jill M, MARSH, Kennan C, HANCOCK, Arthur A, COWART, Marlon D, ESBENSHADE, Timothy A, BRIONI, Jorge D, HONORE, Prisca, SALYERS, Anita K, PAI, Madhavi, ZHU, Chang Z, WENSINK, Erica J, WITTE, David G, MILLER, Thomas R, MIKUSA, Joe P, BAKER, Scott J

“…The histamine H(4) receptor (H(4)R) is expressed primarily on cells involved in inflammation and immune responses. To determine the potential role of H(4)R in…”
Get full text

In vitro and in vivo characterization of A-796260 : a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models: CB2 cannabinoid receptors by YAO, B. B, HSIEH, G. C, SALYERS, A. K, WENSINK, E. J, HONORE, P, SULLIVAN, J. P, DART, M. J, MEYER, M. D, FROST, J. M, FAN, Y, GARRISON, T. R, DAZA, A. V, GRAYSON, G. K, ZHU, C. Z, PAI, M, CHANDRAN, P

Get full text

Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model by Suleymanov, Osman D, Szalony, James A, Salyers, Anita K, LaChance, Rhonda M, Parlow, John J, South, Michael S, Wood, Rhonda S, Nicholson, Nancy S

“…This study was designed to evaluate the antithrombotic efficacy and bleeding propensity of a selective, small-molecule inhibitor of tissue factor/factor VIIa…”
Get more information

Assessment of platelet function assays: Platelet function and monitoring with long-term inhibition of the glycoprotein IIb/IIIa receptor with oral antagonists by NICHOLSON, N. S, PANZER-KNODLE, S. G, HAAS, N. F, TAITE, B. B, SZALONY, J. A, PAGE, J. D, FEIGEN, L. P, LANSKY, D. M, SALYERS, A. K

Get full text

Administration of a small molecule tissue factor/Factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time by Szalony, James A, Suleymanov, Osman D, Salyers, Anita K, Panzer-Knodle, Susan G, Blom, Jason D, LaChance, Rhonda M, Case, Brenda L, Parlow, John J, South, Michael S, Wood, Rhonda S, Nicholson, Nancy S

“…Introduction: Pharmacological treatment of deep vein thrombosis (DVT) in the future may target inhibitors of specific procoagulant proteins. This study used a…”
Get full text